An open-label, multicenter clinical trial to assess the safety and efficacy of three different doses of OPS-2071 in patients with bacterial enteritis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs OPS 2071 (Primary)
- Indications Bacterial infections; Enteritis
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 16 Aug 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
- 16 Aug 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
- 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.